坎伯兰药业 CPIX 深 沪
等待开盘 07-16 09:30:00 美东时间
7.80
+0.815
+11.67%
华盛通- 最 高7.90
- 今 开7.00
- 成交量 10.51万股
- 最 低 7.00
- 昨 收 6.985
- 总市值 1.17亿
- 52周最高 7.90
- 市盈率 静 --
- 换手率 0.70%
- 52周最低 1.85
- 委 比 71.08%
- 总股本 1498.31万
- 历史最高 8.02
- 量 比 0.91
- 振 幅 12.88%
- 历史最低 1.04
- 每 手 1
- 风险率 1.14%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Cumberland Pharmaceuticals Announces Special Dividend, Share Buyback
Cumberland Pharmaceuticals ( ($CPIX) ) has issued an announcement. On July 13, ...
07-14 06:00
Cumberland Pharmaceuticals declares $1.50 dividend
Cumberland Pharmaceuticals (CPIX) declares $1.50/share special dividend. Payable July 31; for shareholders of record July 23; ex-div July 23. See CPIX Dividend Scorecard, Yield Chart, & Dividend Growt...
07-14 00:53
/C O R R E C T I O N -- Cumberland Pharmaceuticals Inc./
/C O R R E C T I O N – Cumberland Pharmaceuticals Inc./ In the news release, CUMBERLAND PHARMACEUTICALS ANNOUNCES SPECIAL DIVIDEND OF $1.50 PER SHARE, issued July 13, 2026 by Cumberland Phar...
07-13 23:20
Cumberland Pharmaceuticals Declares $1.50/Share Special Dividend
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), an innovation-focused biopharmaceutical company developing new products for rare diseases, announced today that its Board of Directors has authorized and declared a special cash dividend of $1.50 per share of the Company's common stock. The dividend wil...
07-13 22:50
Cumberland Pharmaceuticals declares special dividend of $1.5 per share
Cumberland Pharmaceuticals declares special dividend of $1.5 per share Cumberland Pharmaceuticals declared a special cash dividend of USD 1.5 per common share. Payable July 31, 2026, to shareholders of record at the close of business on July 10, 2026. Board also authorized an open-market share repur
07-13 22:47
Cumberland Pharma Advances Duchenne Program With New Safety, Efficacy Data
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) stock is trading higher on Friday following positive updates from the company’s Phase 2 FIGHT DMD trial, which evaluates ifetroban for Duchenne muscular dystrophy (DMD) heart disease. Cumberland Pharma Stock Jumps On Phase 2 FIGHT DMD Trial Update Cumber...
06-27 01:53
RedHill Biopharma Announces Up To $19.4 Million Private Placement
$6 million upfront with up to approximately $13.4 million of potential aggregate gross proceeds upon the exercise in full of warrants TEL AVIV, Israel & RALEIGH, N.C., June 18, 2026 /PRNewsw...
06-18 20:00
RedHill Biopharma posts corporate presentation on Talicia commercialization and GI-focused pipeline
RedHill Biopharma posts corporate presentation on Talicia commercialization and GI-focused pipeline RedHill Biopharma highlighted FY 2025 net revenue of USD 7.8 million, cash balance of USD 4.1 million, gross margin of 74.6%. Market cap shown at about USD 5.2 million; ADS count about 5,200,000; stat
06-15 15:01
U.S. State Dept Announces Nearly $38M In Additional Funding Toward The Department's Ongoing Ebola Response Efforts
https://www.state.gov/releases/office-of-the-spokesperson/2026/06/ebola-response-update-june-5-2026/
06-06 02:24
RedHill Biopharma publishes corporate presentation on GI, infectious disease, oncology pipeline and Talicia commercialization
RedHill Biopharma publishes corporate presentation on GI, infectious disease, oncology pipeline and Talicia commercialization RedHill highlighted Talicia as its marketed product, co-commercialized in the U.S. with Cumberland Pharmaceuticals for adult H. pylori infection. FY 2025 net revenue USD 7.8
05-27 16:47
